Completed OBSERVATIONAL NCT05561712

Method Optimization for the Quantification of the NAD

Method Optimization for the Quantification of the NAD (Nicotinamide Adenine Dinucleotide) Metabolome in Human Whole Blood, Plasma, and Urine, and Evaluation of Baseline Inter and Intra-subject Variability

Sponsor: Société des Produits Nestlé (SPN)

Conditions NAD

Interventions Laboratory method validation

Updated 4 times since 2022 Last updated: Sep 27, 2022 Started: Feb 25, 2022 Primary completion: Mar 15, 2022 Completion: Mar 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates NAD and is currently completed. Société des Produits Nestlé (SPN) leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2023 — Jul 2024 [monthly]

Completed
Oct 2022 — Mar 2023 [monthly]

Completed

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Société des Produits Nestlé (SPN)

Data source: Société des Produits Nestlé (SPN)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lausanne, Switzerland